MCR Acquires Cloud-Based Hotel Management Platform Optii
7.12.2021 17:00:00 EET | Business Wire | Press release
MCR, the 4th-largest hotel owner-operator in the United States and one of Fast Company’s 10 Most Innovative Travel Companies of 2020, has acquired Optii, the only predictive, cloud-based technology for improved hotel operations.
Optii will continue to be a standalone company with its existing management team of CEO Katherine Grass, Founder and CSO Soenke Weiss and CRO Deborah Pevenstein.
MCR’s portfolio of 140 branded and independent hotels will be arms-length customers of Optii, which will continue to offer its product to forward-thinking hotel companies. No data will be shared with MCR. MCR will mobilize its 4,000 hotel team members — who will utilize Optii for 20,000 guestrooms per day — to push for innovative product enhancements.
Stayntouch property management system software, another standalone company owned by MCR, will integrate with Optii.
A data-driven platform powered by artificial intelligence, Optii has revolutionized housekeeping technology, optimizing labor and cleaning sequences for faster turnaround times and reduced costs. With its Service and Chat products, Optii streamlines internal communication, allowing managers to auto-assign and track jobs and guest requests in real time, eliminating calls by 95%. The user-friendly mobile and tablet interface can be accessed anywhere, whether on or off property.
Used by hotels to clean more than 10 million guestrooms globally, Optii has experienced stratospheric growth in the past year as hoteliers seek to increase housekeeping productivity while committing to Covid-19 protocols and facing labor shortages.
Fully configurable, the platform connects to many property management systems and is a best-in-class solution for hotels of all sizes, from 50-room boutique properties to 3,000-room casinos. Unlike any other hotel technology, remote onboarding is led by the experts — former executive housekeepers. The software’s artificial intelligence gets smarter over time — around week four, the technology peaks in providing operational efficiencies.
Optii has an aggressive expansion strategy that includes the imminent introduction of a Preventative Maintenance product.
Katherine Grass, CEO of Optii, says, “We are honored to have been selected by MCR to join their portfolio of companies. This acquisition will significantly boost our ability to provide hotels around the world with the technology they need to succeed in today’s operating environment. More and more hotels are realizing that investing in the right technology at this unique time can be a key lever for success. This is a huge growth opportunity for our company to continue momentum in the United States and Europe as well as to further develop our leadership position in Asia.”
Adds Tyler Morse, Chairman and CEO of MCR, “Innovation is a core value of MCR and the acquisition of Optii forwards our mission. At our 140 hotels, we have used every housekeeping technology on the market — and Optii is simply the best. MCR’s investment in Optii will expand its reach globally and provide the company with the resources to continue introducing cutting-edge technology to the hotel industry.”
About Optii Solutions
Optii, headquartered in Austin, Texas, and with offices in New York, London and Brisbane, is a hotel operations solution that leverages smarter technologies such as artificial intelligence, analytics, messaging and mobility to improve the efficiency and effectiveness of hotel operations teams. Optii operates in real time and allows hotels to streamline operations, reduce costs and enhance the guest experience in proven and tangible ways, without requiring capital expenditure and complex integrations. Optii is used by hotels around the world, including the Venetian Macau, part of Las Vegas Sands, La Cantera Resort & Spa and The Don Cesar in the United States, Okada Manilla Resort & Casino, Doma Hotels, Marriott, IHG and more. For further information about Optii, please visit optiisolutions.com.
About MCR
- 4th-largest hotel owner-operator in the United States
- $4.0 billion portfolio of 140 premium-branded hotels
- MCR operates 8 Marriott brands, 6 Hilton brands and a number of unflagged independent hotels
- 20,000 guestrooms across 34 states and 84 cities
- Founded in 2006
- Offices in New York City, Dallas, Chicago and Richmond, Virginia
- 4,000 team members across the country
- Three-time recipient of the Marriott Partnership Circle Award , the highest honor Marriott presents to its owner and franchise partners
- Recipient of the Hilton Legacy Award for Top Performer
- For the TWA Hotel at New York’s JFK Airport, MCR won the Development of the Year (Full Service) Award at The Americas Lodging Investment Summit (ALIS) , the Urban Land Institute New York Excellence in Hotel Development Award and the American Institute of Architects national Architecture Award, the highest honor given by the AIA
- Named one of Fast Company’s 10 Most Innovative Travel Companies of 2020
- For more information, please visit mcrhotels.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211207005258/en/
Contact information
Ellie Box: ebox@fireoth.com, +44 7974 791119
Sarah Mulder: smulder@fireoth.com, +44 7720401466
info@mcrhotels.com
(203) 682-8277
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 20:52:00 EEST | Press release
International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he has served as pro bono counsel to five Nobel Peace Prize laureates. The New York Times has referred to him as "The Extractor" for his work freeing political prisoners worldwide. Genser's decision to support Yim Leak's team comes as the businessman faces an asset freeze exceeding 20 billion baht (more than U
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 18:38:00 EEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release
Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom